1 |
Developmental pathways and gene function in canine myxomatous mitral valve diseaseLu, Chih Chien January 2015 (has links)
Canine myxomatous mitral valve disease (MMVD) is the most common cardiac disease in dogs affecting all breeds, and it shares many similarities with the equivalent human disease. From the only transcriptomic report for canine MMVD published in 2006, serotonin signalling was identified as a contributing factor and has been widely studied since. Two transcriptomic profiling studies in human MMVD have also identified oxidative stress response and bone morphogenic protein signalling contributing to disease pathology. All studies at the transcriptional level have identified a variety of biological functions in MMVD suggesting dynamic extracellular matrix (ECM) remodelling processes are on-going. Moreover, cellular changes found in MMVD are somewhat reminiscent of the events seen in early heart valve, suggesting possible re-activation of signalling pathways of which those driving development and endothelial-to-mesenchymal transition (EndoMT) are particularly interesting. EndoMT, in which endothelial cells change their identity to mesenchymal phenotype and migrate into the cardiac jelly underneath the endothelium, is a crucial mechanism in valvulogenesis. Whether or not gene regulation of EndoMT and valve development also plays a role in MMVD is unknown. In this study, the MMVD cellular changes in the Cavalier King Charles Spaniel (CKCS), a breed with the highest prevalence, earliest onset, and rapid progression of the disease, was investigated. Secondly, transcriptional profiling was conducted using the latest canine microarray chips, a single affected breed (CKCSs), stringent sample quality control and statistical thresholds, with quantitative polymerase chain reaction (Q-PCR) for data validation. After transcriptional mapping, multi-platform in silico analysis was conducted to identify relationship between differentially expressed genes and their relevant biological functions. Next, a comparison study using immunohistochemistry was performed on different severities of myxomatous valves to localize the proteins of interest. Finally, to model the transcriptional factors and their downstream targets, mitral valve endothelial cell (MVEC) clones were derived from the canine normal mitral valves for future in vitro studies. Cellular changes of MMVD between CKCS and non-CKCS populations showed no difference in their distribution, number and phenotypic markers. Global genomic expression analysis identified similar (inflammation, up-regulation of serotonin receptor and bone morphogenic protein) and novel biological functions (epithelial-to-mesenchymal transition) compared to the previous study in 2006. Key transcriptional factors and genes associated with EndoMT including SNAI1, TAGLN, ACTA2, ACTG2, HAS2, and CTNNB1 were found up-regulated, and NID1, LAMA2, CDH5 were down-regulated in the MMVD group. In myxomatous mitral valves, increased expression of HAS2 in myofibroblasts, SNAI1 expression in endothelial cells, and co-expression of CDH5 and α-smooth muscle actin (α-SMA) also suggested the presence of EndoMT compared to normal valves. Nevertheless, there is also evidence of EndoMT in normal valves (α-SMA positive endothelial cells) which might suggest contribution to life-long valve re-modelling. In addition, there was a decreased expression of microRNAs associated with modulation of extracellular matrix transcripts, including miR-23, miR-29, and miR-218, indicating epigenetic regulation in MMVD. Based on the cellular changes, MMVD in CKCS appears to be representative of MMVD in all breeds and the early-onset of MMVD in that breed does not lead to different end-stage pathology. Novel biological functions such as EndoMT, were identified by transcriptional profiling, and by using powerful bioinformatic tools providing insight into understanding gene regulation in MMVD. Furthermore, a relationship between developmental biology processes and MMVD pathogenesis was established, with a likely important role for epigenetics in disease pathogenesis.
|
2 |
Variabilidade da frequência cardíaca em cães com endocardiose valvar submetidos a treinamento físicoValandro, Marilia Avila 29 March 2016 (has links)
Submitted by Marcos Anselmo (marcos.anselmo@unipampa.edu.br) on 2016-09-08T14:29:39Z
No. of bitstreams: 2
MARILIA AVILA VALANDRO ok.pdf: 1044698 bytes, checksum: 07606147cdffad848dc4db44d0162dd3 (MD5)
license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) / Approved for entry into archive by Marcos Anselmo (marcos.anselmo@unipampa.edu.br) on 2016-09-08T14:30:12Z (GMT) No. of bitstreams: 2
MARILIA AVILA VALANDRO ok.pdf: 1044698 bytes, checksum: 07606147cdffad848dc4db44d0162dd3 (MD5)
license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) / Made available in DSpace on 2016-09-08T14:30:12Z (GMT). No. of bitstreams: 2
MARILIA AVILA VALANDRO ok.pdf: 1044698 bytes, checksum: 07606147cdffad848dc4db44d0162dd3 (MD5)
license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5)
Previous issue date: 2016-03-29 / A endocardiose valvar (EV) é a cardiopatia mais prevalente na espécie canina, capaz de alterar o balanço autonômico pela ativação crônica do sistema nervoso simpático, relacionado ao risco de morte súbita e pior prognóstico. Diversos programas de treinamento com caminhada foram eficazes no restabelecimento do equilíbrio autonômico em seres humanos cardiopata, verificados a luz da variabilidade da frequência cardíaca (VFC). Dessa forma, objetivou-se avaliar o efeito de oito semanas de caminhada, realizadas três vezes por semana, durante 30 a 50 minutos, de moderada intensidade (60 a 80% da frequência cardíaca máxima), sobre a função autonômica cardíaca de cães com EV, utilizando a VFC no domínio do tempo e da frequência como ferramenta. Para tanto, 20 cães com EV foram divididos em dois grupos: grupo controle - não treinado (GC, n=9) e grupo treinamento (GT, n=11), e avaliados nos momentos basal (T0), quatro semanas (T1) e oito semanas (T2). No domínio do tempo, a variável média rMSSD (raiz quadrada da média ao quadrado das diferenças sucessivas entre os intervalos NN) foi maior no GT em quatro (155,5+42,07) e oito semanas (199,8+83,54) em relação ao GC (91,17+35,79 e 88,17+57,51) (p<0,05). No domínio da frequência, a variável High Frequency (HF) foi a mais representativa, e apresentou aumento no GT (30950+25810) após quatro semanas quando comparado ao GC (19090+23210) (p<0,05) e dentro do grupo GT após oito semanas de treinamento (40300+33870) em relação à avaliação basal (29340+20950) (p<0,05). As demais variáveis não sofreram influências do programa de treinamento proposto. Esses resultados demonstram que o treinamento físico com a utilização de caminhadas foi capaz de alterar a VFC, indicando uma maior participação parassimpática em cães com EV. / Valvular endocardiosis is the most prevalent cardiopathy in canine specie. This disease is able to change autonomic balance, which is related to sudden death and worse prognostic, through chronic activation of sympathetic nervous system. Looking at heart rate variability, various walk training plans were efficient for the autonomic balance reestablishment in cardiophats people. In this way, this study focused on evaluate the effect of 8 weeks walking plan on cardiac autonomic function of dogs with valvular endocardiosis. These walking plans were consisted of moderated intensity walking (reaching from 60 to 80% of maximum heart rate) during 30 to 50 minutes, three times a week. Heart rate variability was analyzed by utilizing time and frequency domain as a tool. Thus, 20 dogs with valvular endocardiosis were divided into two groups: Control group, with no training (CG, n=9), and Training group (TG, n=11). They were evaluated at basal moment (T0), 4 weeks (T1), and 8 weeks (T2). At time domain, only the medium variable rMSSD (the root mean square of successive differences between the square NN intervals) was higher in the TG in four (155.5+42.07) and eight weeks (199.8+83.54) than CG (91.17+35.79 and 88.17+57.51) (p<0.05). At frequency domain, the high frequency variable was the most representative and after four weeks, it showed higher on TG (30950+25810) than CG (19090+23210) (p<0.05). After eight weeks, within TG there was higher frequency (40300+33870) when compared to basal evaluation (29340+20950) (p<0.05). The proposed training program did not affect the other variables. These results suggest that the physical training with utilization of walking plans were able to change the heart rate variability what indicated a higher parasimpathetic participation of dogs with valvular endocardiosis.
|
3 |
Echocardiographic Investigation of Canine Myxomatous Mitral Valvular DiseaseWesselowski, Sonya Rae 14 July 2014 (has links)
Objectives: To further characterize the echocardiographic anatomy of the canine mitral valve in healthy dogs and those affected by myxomatous mitral valve disease (MMVD), and to compare the level of agreement between two methods of assessment of left atrial size in identification of left atrial enlargement in dogs with MMVD.
Animals: Sixty dogs with MMVD and 22 normal dogs were prospectively studied with 2-dimensional echocardiography.
Methods: The length (AMVL), width (AMVW) and area (AMVA) of the anterior mitral valve leaflet and the diameter of the mitral valve annulus in systole (MVAs) and diastole (MVAd) were measured. Left atrial size was evaluated with the left atrial to aortic root ratio (LA:Ao) and by measuring left atrial volume indexed to body weight (LA Vol/BW). All patients were staged using published ACVIM guidelines and separated into groups B1 and B2/C.
Results: Measurements of AMVL, AMVW, AMVA, MVAs and MVAd were all significantly greater in the B2/C group than in the control group. AMVW was significantly greater in group B1 than control. Twelve dogs had left atrial enlargement identified with LA Vol/BW that were considered normal using LA:Ao. Diagnostic disagreement between these two measurements was significant (P = 0.00012). The majority of dogs with diagnostic disagreement had concurrent echocardiographic evidence of more advanced mitral regurgitation.
Conclusions: Relative to normal dogs, AMVL, AMVW, AMVA, MVAs and MVAd are greater in patients with advanced MMVD. LA Vol/BW may be superior to LA:Ao for identification of mild left atrial enlargement. / Master of Science
|
4 |
Study of collagen structure in canine myxomatous mitral valve diseaseHadian, Mojtaba January 2009 (has links)
Myxomatous mitral valve disease (MMVD) is the single most common acquired cardiac disease of dogs, and is a disease of significant veterinary importance. It also bears close similarities to mitral valve prolapse in humans and therefore is a disease of emerging comparative interest. Realising the importance of collagen fibres in mitral heart valves and considering the paramount significance of myxomatous mitral valve disease, a better understanding of the pathogenesis of MMVD is essential. Thus, this study was designed to investigate the changes in collagen molecules, including fibril structure, fibril orientation, d-spacing, collagen density, collagen content, thermal stability, and the status of mature and immature crosslinks. A combination of biophysical and biochemical tools such as x-ray diffraction, neutron diffraction, HPLC were utilised in order to fulfil the objectives. Biochemical assay of hydroxyproline revealed a 10% depletion of collagen in mildly affacted (grade I and II) leaflets, while a 20% depletion of fibrillar collagen was revealed by mapping the collagen fibrils onto the anatomy of cardiac leaflets using x-ray data. Differential scanning calorimetry showed that there were no significant differences in the onset temperature of denaturation of collagen between the healthy and affected leaflets. However, in affected areas of leaflets, the enthalpy of denaturation significantly dropped by 20%. In the affected regions, neutron diffraction results showed an increase in the immature reducible cross-links though the low number of the samples can be considered a limiting factor in this regard. However, the HPLC results showed a 25% decrease in the number of mature cross-links. Additionally, the recently introduced imaging technologies to biology and medicine such as differential enhancing imaging (DEI) and coherent anti-Stokes Raman scattering spectroscopy (CARS) were, to the author’s best knowledge, applied for the first time to this disease. In doing so, this thesis furthers our understanding of the pathogenesis of MMVD, especially in relation to the collagen. The thesis provides new findings about MMVD and demonstrates the potential of biophysical tools for studying similar conditions.
|
5 |
Morphological, cellular and proteomic features of canine myxomatous mitral valve diseaseHan, Richard I-Ming January 2009 (has links)
Myxomatous mitral valve degeneration (MMVD) is the single most common cardiac disease of the dog, and is analogous to Mitral Valve Prolapse in humans. Very little is known about the aetiopathogenesis of this disease or the changes in valvular interstitial cell populations in diseased valves. The aim of this study was to identify morphological, cellular and molecular changes associated with MMVD. Mitral valve leaflets from both normal and varying grades (Whitney’s 1-4) of diseased dogs were subject to image analysis, immunophenotyping, proteomics and RT-PCR. Image analysis - leaflet thickening due to accumulation of glycosaminoglycan was significant in this disease. MMVD is associated with loss of connective tissue, reduction in cell numbers but no change in cell shape in the overtly myxomatous area. Near the surface, increase in valvular interstitial cells (VIC) towards the damaged endothelium in concert with destruction of collagen and building up of ground substance was manifested during the disease process. Immunophenotyping - activated myofibroblasts were increased and fibroblast-like VICs were reduced without any change in desmin and myosin expression in MMVD compared to clinical normal dogs. In addition, other cell types like macrophage, adipocyte, chondrocyte, mast cell, and stem cell were identified and their possible role in MMVD is discussed. Proteomics - a protein expression profile was established, with 64 proteins being positively identified from dog’s mitral valve using 1-D SDS PAGE LC/MS. Amongst them 44 proteins were differentially expressed comparing normal and severely diseased. Two actin binding proteins, tropomyosin alpha and myosin light chain-2 were found to be differentially expressed in the normal but down regulated in the diseased. RT-PCR was used to assess the expression of 8 genes of interest. Their expression was compared with 3 different housekeeping genes.
|
6 |
Avaliação clínica da utilização do furosemida, maleato de enalapril, espironolactona e suas associações, em cães com endocardiose de vávula mitralFranco, Rodrigo Prevedello [UNESP] 27 April 2009 (has links) (PDF)
Made available in DSpace on 2014-06-11T19:23:46Z (GMT). No. of bitstreams: 0
Previous issue date: 2009-04-27Bitstream added on 2014-06-13T19:30:22Z : No. of bitstreams: 1
franco_rp_me_jabo.pdf: 1325167 bytes, checksum: c0d65b611313afe6bf052d1a43166362 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / A endocardiose da válvula mitral é uma cardiopatia de alta incidência na clínica médica de pequenos animais, com maior acometimento de cães idosos e de raças de pequeno porte. Realizou-se então um estudo para avaliar clinicamente a utilização do maleato de enalapril, furosemida, espironolactona e suas associações, em cães com endocardiose de válvula mitral classes funcionais Ib e II, antes e após a terapêutica implantada. Para isso, utilizaram-se 36 animais portadores desta afecção, distribuídos em quatro grupos, conforme as classes funcionais de ICC, com terapêutica específica implantada durante 56 dias em cada grupo estudado. Animais portadores da classe funcional Ib foram distribuídos em dois grupos, com o primeiro recebendo furosemida (n=8) e o outro maleato de enalapril (n=8). Igualmente, distribuíram-se os animais da classe funcional II, com um grupo recebendo maleato de enalapril e furosemida (n=10) e o segundo, enalapril associado à espironolactona e furosemida (n=10). Todos os grupos foram avaliados em quatro momentos (T0, T14, T28 e T56 dias) quanto aos parâmetros e sinais clínicos, exames hematológicos e bioquímico-séricos, que incluíram enzima conversora da angiotensina (ECA) e aldosterona; avaliações radiográficas, eletrocardiográficas, ecodopplercardiográficas e da pressão arterial. Os resultados demonstraram uma redução dos sinais clínicos nos animais classe II, com a estabilização dos parâmetros em ambos os grupos. As avaliações hematológica e bioquímico sérica não revelaram alterações significativas nas classes estudadas, mas uma redução significativa dos valores de ECA e aldosterona foram observadas nos grupos que receberam enalapril como terapêutica. Ao exame radiográfico observou-se redução dos valores de VHS e, ao eletrocardiograma as variáveis onda Pms e Complexo QRSms apresentaram diminuições significativas... / The endocardiosis of mitral valve is a high incidence of heart disease in the medical clinic for small animals, with the involvement of older dogs and small breeds. This is a clinical study to evaluate the use of the enalapril maleate, furosemide, spironolactone and their associations in dogs with mitral valve endocardiosis of class Ib and II, before and after therapy implanted. It was used 36 animals with this endocardiosis, divided into four groups according to class of congestive heart failure, implanted with a specific therapy for 56 days in each group. The animals classified in class Ib was divided into two groups, with the first receiving furosemide (n = 8) and the other of maleate of enalapril (n = 8). It is also divided the animals of Class II, with a group of receiving maleate of enalapril and furosemide (n = 10) and second, enalapril combined with spironolactone and furosemide (n = 10). Every groups were available in four moments (T0, T14, T28, e T56 days) as to clinical parameters, symptoms, serum biochemical and hematological tests, which included the angiotensin converting enzyme (ACE) and aldosterone; radiographic evaluations ECG, Dopplerechocardiography and blood pressure. The results showed a reduction of clinical signs in animals Class II, with stabilization of physiological parameters in both groups. The serum biochemical and hematological evaluation showed no significant changes in the classes studied, but a significant reduction of the values of ACE and Aldosterone were seen in the groups receiving enalapril as therapy. By radiographic examination, we observed a reduction of the values of VHS, and the variables Pms wave and QRSms Complex in electrocardiogram showed significant variations in groups of Class II. The absence of variations in blood pressure was observed in both groups. But the Dopplerechocardiogram showed a ventricular remodeling with a significant decrease... (Complete abstract click electronic access below)
|
7 |
Avaliação clínica da utilização do furosemida, maleato de enalapril, espironolactona e suas associações, em cães com endocardiose de vávula mitral /Franco, Rodrigo Prevedello. January 2009 (has links)
Orientador: Aparecido Antonio Camacho / Banca: Áureo evangelista Santana / Banca: Wagner Luís Ferreira / Resumo: A endocardiose da válvula mitral é uma cardiopatia de alta incidência na clínica médica de pequenos animais, com maior acometimento de cães idosos e de raças de pequeno porte. Realizou-se então um estudo para avaliar clinicamente a utilização do maleato de enalapril, furosemida, espironolactona e suas associações, em cães com endocardiose de válvula mitral classes funcionais Ib e II, antes e após a terapêutica implantada. Para isso, utilizaram-se 36 animais portadores desta afecção, distribuídos em quatro grupos, conforme as classes funcionais de ICC, com terapêutica específica implantada durante 56 dias em cada grupo estudado. Animais portadores da classe funcional Ib foram distribuídos em dois grupos, com o primeiro recebendo furosemida (n=8) e o outro maleato de enalapril (n=8). Igualmente, distribuíram-se os animais da classe funcional II, com um grupo recebendo maleato de enalapril e furosemida (n=10) e o segundo, enalapril associado à espironolactona e furosemida (n=10). Todos os grupos foram avaliados em quatro momentos (T0, T14, T28 e T56 dias) quanto aos parâmetros e sinais clínicos, exames hematológicos e bioquímico-séricos, que incluíram enzima conversora da angiotensina (ECA) e aldosterona; avaliações radiográficas, eletrocardiográficas, ecodopplercardiográficas e da pressão arterial. Os resultados demonstraram uma redução dos sinais clínicos nos animais classe II, com a estabilização dos parâmetros em ambos os grupos. As avaliações hematológica e bioquímico sérica não revelaram alterações significativas nas classes estudadas, mas uma redução significativa dos valores de ECA e aldosterona foram observadas nos grupos que receberam enalapril como terapêutica. Ao exame radiográfico observou-se redução dos valores de VHS e, ao eletrocardiograma as variáveis onda Pms e Complexo QRSms apresentaram diminuições significativas... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: The endocardiosis of mitral valve is a high incidence of heart disease in the medical clinic for small animals, with the involvement of older dogs and small breeds. This is a clinical study to evaluate the use of the enalapril maleate, furosemide, spironolactone and their associations in dogs with mitral valve endocardiosis of class Ib and II, before and after therapy implanted. It was used 36 animals with this endocardiosis, divided into four groups according to class of congestive heart failure, implanted with a specific therapy for 56 days in each group. The animals classified in class Ib was divided into two groups, with the first receiving furosemide (n = 8) and the other of maleate of enalapril (n = 8). It is also divided the animals of Class II, with a group of receiving maleate of enalapril and furosemide (n = 10) and second, enalapril combined with spironolactone and furosemide (n = 10). Every groups were available in four moments (T0, T14, T28, e T56 days) as to clinical parameters, symptoms, serum biochemical and hematological tests, which included the angiotensin converting enzyme (ACE) and aldosterone; radiographic evaluations ECG, Dopplerechocardiography and blood pressure. The results showed a reduction of clinical signs in animals Class II, with stabilization of physiological parameters in both groups. The serum biochemical and hematological evaluation showed no significant changes in the classes studied, but a significant reduction of the values of ACE and Aldosterone were seen in the groups receiving enalapril as therapy. By radiographic examination, we observed a reduction of the values of VHS, and the variables Pms wave and QRSms Complex in electrocardiogram showed significant variations in groups of Class II. The absence of variations in blood pressure was observed in both groups. But the Dopplerechocardiogram showed a ventricular remodeling with a significant decrease... (Complete abstract click electronic access below) / Mestre
|
8 |
Targeted macrophage depletion is protective against heart valve disease in Marfan syndromeKim, Andrew 14 October 2019 (has links)
No description available.
|
9 |
Cellular Mechanisms of VIC Activation in Mitral Valve ProlapseDye, Bailey Katherine January 2020 (has links)
No description available.
|
10 |
Tissue-engineered canine mitral valve constructs as in vitro research models for myxomatous mitral valve diseaseLiu, Mengmeng January 2014 (has links)
Myxomatous mitral valve disease (MMVD) is one of the most common degenerative cardiac diseases affecting humans and dogs; however, its pathogenesis is not completely understood. This study focussed on developing tissue-engineered fibrin based canine mitral valve constructs, which can be used as an in vitro platform to study the pathogenesis of MMVD. Prior to three dimensional (3D) construct fabrication, primary canine mitral valve endothelial cells (VECs) and valve interstitial cells (VICs) were isolated, cultured and characterized utilising a variety of techniques. Moreover, preliminary experiments were carried out to optimise the purity of VEC cultures. It is uncertain if canine MMVD is initiated by long term shear stress damage to the valve endothelium or from abnormalities of VICs. To investigate both hypotheses, three types of models were produced using fibrin/based 3D culture techniques: healthy VEC-VIC co-culture (Type 1); healthy VEC-diseased VIC co-culture (Type 2); healthy VEC-VIC co-culture with endothelial damage during culture (Type 3). Histological examination demonstrated partial native tissue-like morphology of the 3D constructs. Results suggest that current static cultured constructs express MMVD markers irrespective of using healthy or diseased VICs. Simple mechanical stimulation was found to regulate VIC activity in the 3D models. Endothelial damage resulting in VIC phenotypic activation (a change typically observed in MMVD), and decreased mechanical tension appeared to be a negative regulator of this effect. Moreover, there appears to be heterogeneity in the activated VIC population. Additionally, distinct advanced glycation end product (AGE) carboxymethyllysine (CML) expression was found in canine MMVD valves, which suggesting this biochemical compound (known to affect long living protein) might be a putative regulator of MMVD pathogenesis. The role of CML in MMVD can be further investigated utilizing current 3D static mitral valve construct model in future studies. Lastly a prototype dynamic tubular construct and a customised bioreactor system were developed. Preliminary data suggest the feasibility of tubular construct fabrication and endothelialisation, which provides foundation for future dynamic conditioning experiments and will allow examination of the role of endothelial shear stress in triggering MMVD. In summary, this project successfully developed fibrin based canine mitral valve constructs. It is believed they are promising models for MMVD research, allowing new insights in understanding MMVD pathogenesis.
|
Page generated in 0.0594 seconds